Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress
- 18 August 2017
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 55 (1) , 138-144
Abstract
Soluble epoxide hydrolase (sEH) is widely expressed in the mammalian brain and possesses dual enzymatic activities, including C-terminal epoxide hydrolase (C-EH) which degrades epoxyeicosatrienoic acid (EET), a beneficial arachidonic acid metabolite. In the present study, the neuroprotective effect of sEH inhibition on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration of nigrostriatal dopaminergic system was investigated using genetic and pharmacological approaches. MPTP (15 mg/kg) was intraperitoneally injected in sEH knockout (KO) mice and C57BL/6J mice as wild-type (WT) mice. Compared with the MPTP-treated WT mice, MPTP-induced reductions in striatal dopamine content and nigral tyrosine hydroxylase level (TH, a biomarker of dopaminergic neurons) were less significant in the treated sEH mice. Furthermore, MPTP-induced HO-1 elevation (a redox-regulated protein), α-synuclein aggregation, and caspase 12 activation (a hallmark of ER stress) were less prominent in sEH KO mice than in WT mice. These data indicate that sEH KO mice are more resistant to MPTP-induced neurotoxicity. The pharmacological effect of N-[1-(1-oxopropyl)-4-piperidinyl]-N0-[4-(trifluoromethoxy)phenyl)-urea (TPPU, an sEH inhibitor) on MPTP-induced neurotoxicity was investigated in WT mice. TPPU (1 mg/kg, i.p.) attenuated MPTP-induced reduction in striatal dopamine content, TH-positive cell numbers, TH, and pro-caspase 9 protein levels (an initiator caspase of apoptosis) in mouse SN. Moreover, TPPU reduced MPTP-induced HO-1 elevation, α-synuclein aggregation and caspase 12 activation, indicating that TPPU is effective in attenuating MPTP-induced oxidative stress, apoptosis, protein aggregation, and ER stress. In conclusion, our study suggests that sEH is a potential target for developing therapies for parkinsonism. Furthermore, sEH inhibitors may be of clinical significance for treating CNS neurodegenerative diseases.Keywords
This publication has 35 references indexed in Scilit:
- An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to TherapeuticsCNS & Neurological Disorders - Drug Targets, 2016
- Protein aggregation and ER stressBrain Research, 2016
- Epoxyeicosanoid Signaling Provides Multi-target Protective Effects on Neurovascular Unit in Rats After Focal IschemiaJournal of Molecular Neuroscience, 2015
- Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injuryMolecular Neurobiology, 2015
- The Protective Effect of Epoxyeicosatrienoic Acids on Cerebral Ischemia/Reperfusion Injury is Associated with PI3K/Akt Pathway and ATP-Sensitive Potassium ChannelsNeurochemical Research, 2014
- Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced ParkinsonismMolecular Neurobiology, 2014
- Alpha-synuclein: from secretion to dysfunction and deathCell Death & Disease, 2012
- Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic systemNeuropathology and Applied Neurobiology, 2010
- Heme oxygenase‐1 and neurodegeneration: expanding frontiers of engagementJournal of Neurochemistry, 2009
- Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoidsArchives of Biochemistry and Biophysics, 2005